LONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Gastric cancer, colorectal cancer, breast cancer, combination with cisplatin for metastatic and advanced lung cancer, head & neck cancer, and adjuvant treatment for T2 stage IB lung adenocarcinoma.
Gemmis is indicated for the treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer and biliary tract cancer. Gemmis is indicated in combination with paclitaxel for anthracycline-treated failure locally-recurred inoperable breast cancer or metastatic breast cancer after failure of prior anthracycline-containing adjuvant or metastatic chemotherapy. Gemmis is indicated in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. Biliary tract cancer.
Irino is indicated for the treatment of patients with advanced colorectal cancer:
1. In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
2. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
3. In combination with cetuximab, it is used to treat patients with KRAS wild-type metastatic colorectal cancer who have failed cytotoxic therapy with irinotecan and have epithelial growth factor receptor (EGFR) phenotype. (See Pharmacodynamic Properties)
4. In combination with 5 fluorouracil, folinic acid, and bevacizumab as the first-line treatment for patients with metastatic colorectal or rectal cancer.
5. In combination treatment with capecitabine as first-line treatment for patients with metastatic colorectal cancer.
6. In combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFIRINOX) as the first-line treatment for metastatic pancreatic cancer.
7. For patients with unresectable locally advanced and recurrent/metastatic gastric cancer.
Mammary carcinoma, malignant lymphoma, soft tissue sarcoma, and gastric, lung and ovarian carcinomas.
Breast cancer, non-small cell lung cancer, prostate cancer, head and neck cancer, gastric adenocarcinoma.
To diminish the toxicity and counteract the effect of unintentional over dosage of folic acid antagonist. To treat Folate deficient megaloblastic anemias of infancy, pregnancy, sprue, and nutritional deficiencies.
For the treatment of patients with unresectable or metastatic liposarcoma (liposarcoma) or leiomyosarcoma (leiomyosarcoma) who have received a course of treatment containing anthracycline.
For adults with locally advanced or metastatic cholangiocarcinoma who have received systemic drug therapy and whose tumor has FGFR2 fusions or rearrangements, unresectable condition.
Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation (ASCT) when used in combination with lenalidomide or as a single agent.
Indicated for the treatment of patients with high risk myelodysplastic syndrome: refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Arsenic trioxide is indicated for the induction of remission and consolidation of acute promyelocytic leukemia characterized by t (15,17) translocation or PML/RAR-alpha gene expression, in patients who are refractory to or have relapsed from retinoid and anthracycline chemotherapy.
The effect of Trioxide on other acute myeloid leukemias has not been studied.
1. Lenalidomide in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation (ASCT).
2. To be used in combination with dexamethasone for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy.
1. Used in combination with other cancer treatment drugs for untreated multiple myeloma (MM) patients and who have received at least one treatment modality or patients with advanced multiple myeloid cancer who are not suitable for bone marrow transplantation.
2. For Mantle Cell Lymphoma (MCL) patients.
Pomalidomide is a thalidomide analogue, used in combination with dexamethasone, approved for use in patients with multiple myeloma who have previously received at least two therapies containing lenalidomide and bortezomib, and are confirmed to have disease progression by completed the previous treatment or 60 days after the completion of treatment.
Painkyl is an opioid analgesic indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking at least: 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.
Anorexia in patients with AIDS, and significant weight loss due to AIDS or cancer-related cachexia.
Granisetron extended-release subQ injection is indicated for the prevention of acute and delayed chemotherapy-associated nausea and vomiting in patients receiving regimens with an anthracycline in combination with cyclophosphamide.
It may be used for initial and repeat chemotherapy courses, and must be used in combination with other antiemetics (eg, dexamethasone, neurokinase-1 receptor antagonists).
Bone metastases from solid tumors: Treatment of documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy); prostate cancer should have progressed following treatment with at least one hormonal therapy.
Hypercalcemia of malignancy: Treatment of hypercalcemia (albumin-corrected serum calcium ≥12 mg/dL) of malignancy. Multiple myeloma: Treatment of osteolytic lesions of multiple myeloma.